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Alzheimer’s disease (AD) is the most frequent neurodegenerative disorder leading to dementia in the aged human population. It
is characterized by the presence of two main pathological hallmarks in the brain: senile plaques containing β-amyloid peptide and
neuroﬁbrillarytangles(NFTs),consistingofﬁbrillarpolymersofabnormallyphosphorylatedtauprotein.Bothofthesehistological
characteristics of the disease have been simulated in genetically modiﬁed animals, which today include numerous mouse, ﬁsh,
worm, and ﬂy models of AD. The objective of this review is to present some of the main animal models that exist for reproducing
symptoms of the disorder and their advantages and shortcomings as suitable models of the pathological processes. Moreover, we
will discuss the results and conclusions which have been drawn from the use of these models so far and their contribution to the
development of therapeutic applications for AD.
1.Introduction:Alzheimer’sDisease,
Neuropathology, andClinicalCharacteristics
Senile plaques and neuroﬁbrillary tangles are the two main
histopathological characteristics of Alzheimer’s disease. They
were described for the ﬁrst time by Alois Alzheimer in
1907, who discovered both structures in the autopsy of a
brain from a patient who had exhibited severe cognitive
impairment and memory loss. Although these hallmarks
of the disease were established as long as a hundred years
ago, the illness was not fully recognized as such due to the
social dismissal of dementia as a normal part of the human
ageing process [1]. From the late 1970s onwards however,
extensive neurobiological research has been in progress
to understand the disease and to develop therapeutic
approaches.
Today it is widely accepted that the basis for AD is
biological and that senile plaques and neuroﬁbrillary tangles
are responsible for the inception of the disorder and also that
especially the number of NFTs is proportionally related to
theseverityoftheaccompanyingsymptoms,suchasmemory
loss, confusion, and cognitive failure. Plaques and tangles
can be found post mortem mainly in the hippocampus and
cerebral cortex but also in other areas of the brain important
for cognitive functioning.
Early and late onset AD as well as familial and sporadic
AD are distinguished based on the time in life of the patient
when symptoms ﬁrst occur and the involvement of gene
mutations or chromosomal aberrations that can be related
to the disease, respectively. Nevertheless, in all cases the
development of histopathological and behavioral symptoms
is similar to indistinguishable. Several genetic factors have
been described in relation with early and late onset familial
AD, though their involvement is not per se essential for
development of the disorder, given that only about 1% of all
cases of Alzheimer’s are familial.
However, studying how these genetic inﬂuences may be
able to induce the symptoms characteristic for AD could
be a step towards understanding the mechanisms of the
disease and lead scientists towards future clinical therapeutic
approaches. Late onset familial AD may involve various
susceptibility genes [2, 3]. The most studied is the APOE
e4 allele of the gene coding for Apolipoprotein E. Though
the underlying mechanism is still unknown, proof exists that2 International Journal of Alzheimer’s Disease
this allele causes a shift in age of onset towards a younger
age [4]. In early onset familial AD, mutations have been
described in three genes involved in senile plaque formation,
namely APP, PSEN1, and PSEN2 which encode the proteins
Amyloid precursor protein, presenilin-1, and presenilin-2,
respectively. The presenilins are integral membrane proteins
that form part of the γ-secretase complex that, after β-
secretase cleavage of the Amyloid precursor protein, gener-
ates the amyloid β (Aβ) fragment. Mutations in PSEN1 and
PSEN2 are believed to possibly contribute to an increase in
Aβ, especially the more neurotoxic form comprised of 42
amino acids, Aβ42. Mutated forms of human APP have been
expressed in a variety of transgenic animal models to further
the understanding of plaque formation.
Other contributing factors to the pathogenesis of AD
are being addressed in various studies, and today lifestyle
choices, adequate nutrition, psychological well being, and
intellectual stimulation are proven to exert important inﬂu-
ence on susceptibility to AD and other forms of dementia [5,
6]. The understanding and distribution of this information
may not provide a cure but help to prevent the development
or lower the severity of AD symptoms in many cases.
1.1. Senile Plaques. Senile plaques are formed via the
aggregation of amyloid β outside neuronal cells. While Aβ
is a naturally occurring 4kDa polypeptide in the brain, it
becomes neurotoxic in excess quantities or when it fails
to be degraded so that polymerization occurs. Extracellular
plaques developing in this manner act as synaptotoxins
blocking the communication between neurons.
Plaques are formed mostly from Aβ derived from
amyloid precursor protein (APP) which is an integral
membrane protein type I of unknown function which occurs
in diﬀerent isoforms. The most common isoform which is
expressed exclusively in neurons is APP695, comprised of
695 amino acids. APP contains various domains: a single
transmembrane domain, an extramembranous N-terminal
domain, and a cytoplasmic region at its C-terminus as well
as a signal sequence. The neurotoxic eﬀects of APP are
believed to be mediated by proteolytic processing of APP
which gives rise to Aβ [7]. β-secretase (BACE1, cleaving
enzyme of the β-site of APP) liberates the amino terminal
fragment of Aβ while the subsequent cleavage by γ-secretase
of the resulting C-terminal fragment determines the overall
length of the amyloid peptide, giving rise to Aβ40, and the
less common but more neurotoxic form Aβ42. α-secretase
cleavage of APP does not contribute to plaque formation
due to the fact that this cleavage takes place inside the Aβ
regionofAPP.Aβisbelievedtobeoneoftheprincipalfactors
which causes neurodegeneration in Alzheimer’s disease by
forming oligomeric aggregates leading to accumulation of
these structures in the brain [8]. Aβ42 is considered to be
more prone to aggregation and probably acts as a catalyst for
the aggregation of Aβ40 [8].
1.2. Neuroﬁbrillary Tangles. Neuroﬁbrillary tangles (NFT)
are the second histopathological hallmark found in brains
aﬀected by AD. These intraneuronal lesions consist princi-
pally of aberrant ﬁlaments, the principal proportion (95%)
being paired helical ﬁlaments (PHFs), and the rest being
straight ﬁlaments (SFs). PHFs are bundles made up of
twisted ﬁlaments, which like SFs, are composed of aberrantly
hyperphosphorylatedtauprotein[9,10].Thediameterrange
of PHFs is 8–20nm and they exhibit periodic repeats of
80nm along their length while straight ﬁlaments do not
show this periodicity and have a diameter of 15nm [11].
PHFs are also the components of the neuropil threads,
which appear independently of plaques and tangles and
may be observed in an array of dystrophic neurites. Not
all neuronal cell types appear to develop neuroﬁbrillary
tangles. In the cerebral cortex, all cells containing NFTs
are pyramidal neurons, while in the subcortical nuclei the
most aﬀected cells are the ones with extremely long axons,
consistent with the observation of thin long neurites being
especially vulnerable to AD-related cytoskeletal changes
[12].
NFTs also appear independently from the presence of
senile plaques in other neurodegenerative disorders such
as Pick’s disease, Progressive supranuclear palsy [13], fron-
totemporal dementia and parkinsonism linked to chro-
mosome 17 [14], meningioangiomatosis [15], or subacute
sclerosing panencephalitis [16].
Under normal physiological conditions however, tau is
a phosphoprotein that plays an important role in a variety
of processes. Besides its crucial role in tubulin assembly and
microtubule stabilization [17, 18], it is also important for
the outgrowth of neurites from the cell body [19]. Recently,
tau has also been observed to be involved in the migration
of new neurons [20]. The authors detected phosphorylated
tau protein in newly generated neurons in two well-known
regions of adult neurogenesis, the subventricular zone
associated with the lateral ventricles and the subgranular
zone of the hippocampus. In these zones, phosphorylated
tau was colocalized with doublecortin, a cytoskeletal protein
that serves as a marker for neuronal migration, while tau
knockout mice showed similar numbers of doublecortin-
expressing cells but also a signiﬁcant decrease in migration
of these cells. The obtained results suggest a function for tau
in the migration of newborn neurons in adult neurogenesis.
The modiﬁcation of the tau protein by phosphorylation
can alter the way it interacts with microtubules, as is the
case with AD. There, hyperphosphorylation induces tau to
dissociate from the microtubules which depolymerize while
the concentration of soluble tau in the cells increases. This
eﬀect contributes to the assembly of ﬁlaments and the
creation of PHFs from the soluble pool of tau. As neu-
roﬁbrillary tangles are composed mainly of PHFs and their
number in the brain has been described to be proportional
to the severity of symptoms of dementia, phosphorylation
of tau appears to play a major role in the pathogenesis of
AD.
Given these observations, it would be of great interest
to determine the enzymes that phosphorylate tau in the
brain. One of them has been identiﬁed as the kinase GSK-
3. As an example, in a Drosophila melanogaster model,
tau phosphorylation via its GSK-3 homologue Shaggy has
been described to facilitate its aggregation to ﬁlamentous
structures [21].International Journal of Alzheimer’s Disease 3
For an extensive explanation of tau and its role under
physiological and pathological conditions, see the review
published by our group [22].
An alternative interpretation of the role of phospho-
rylated tau protein has been promoted by the group of
Mark A. Smith [23]. These authors question the concept
that phospho-tau is inherently toxic because of its presence
in neuroﬁbrillary tangles and must therefore be a direct
mediator of the disease. Instead, tau aggregation could be
a response to the disease, and actually play the role of
a protective shield against neurotoxic agents rather than
leading to neurodegeneration. In support of this model
Castellani and coworkers point out that NFTs, (a) are found
in viable neuronal cells even in late stages of AD, (b)
exist in the neuronal cytoplasm for decades, (c) can be
observed, sometimes at high concentrations, in the brains of
elderly persons who showed no signs of dementia through-
out their lifetime, and (d) are present in neurons which
contain normal amounts of structurally intact microtubules
[24].
2. AnimalModels for AD and
RelatedTauopathies
Several animal models of AD have been created in order
to emulate speciﬁc features of the disease, such as its
histopathological, biochemical, and behavioral characteris-
tics. These models were designed to probe the pathological
and biochemical changes that take place in aﬀected organ-
isms throughout the progression of the disorder and to test
for possible therapeutic measures to be applied in the future
in human patients.
The usefulness of an animal model depends on its
capability of faithfully replicating the physiological processes
that take part in the progress of the disease in human
patients so that it leads to a better comprehension of
the pathogenesis and ﬁnally allows developing an eﬃcient
therapeutic approach.
Since no other natural species spontaneously produce all
ofthehistopathological,cognitive,andbehavioralsymptoms
that characterize Alzheimer’s, there was a need for the
development of transgenic animal models or of dietary
manipulation of test animals which would allow reproduc-
tion of the hallmarks of AD. From a practical viewpoint, it is
of great importance to choose animals with a short lifespan
and fast rates of ageing in order to be able to observe, in a
reasonable time window, processes which take from 50 to 80
years in humans to appear and develop.
Each animal model has its limitations and advantages,
as to date, none are able to express the whole set of
characteristics needed to resemble full-blown AD pathology
(Table 1).Thecontributionofeachmodeltotheunderstand-
ing of this devastating disease, however, is immeasurable
and has permitted the scientiﬁc community to establish an
extensive base of knowledge on AD and the mechanics of
the disorder. In the following, we will present the diﬀerent
animal models which have been established so far, discuss
their characteristics, advantages, and pitfalls as well as take
a look at the latest developments in this ﬁeld of research.
2.1. Lower Eukaryote Models. Diﬀerent invertebrate models
have been created for studying Alzheimer’s disease, the most
commonly used organism being the fruit ﬂy Drosophila
melanogaster. Besides being easy to breed, manipulate, and
genetically modify, D. melanogaster presents the advantage
of having an extremely short development time spanning
only 12 days from a fertilized egg to an adult ﬂy, so the
generation of large numbers of oﬀspring is very easy. In
onemodel,transgenicDrosophilaexpressedhumanwildtype
andR406mutanttau[25].Althoughoverexpressionofeither
tau form led to the premature death of the ﬂies, symptoms of
progressiveneurodegenerationweremorepronouncedinthe
strain carrying the mutant gene. Intriguingly, the symptoms
of neurodegeneration were not accompanied by the forma-
tion of neuroﬁbrillary tangles. However, when ﬂies which
expressed wild type tau were induced to also overexpress
the Drosophila GSK-3 homologue shaggy, neuroﬁbrillary
lesions could be observed. These ﬁndings indicate that
higher levels of tau phosphorylation cause its aggregation
into ﬁlaments and thus indicate an important role for
GSK-3 in contributing to the formation of neuroﬁbrillary
tangles in AD. Drosophila was also used to investigate the
neurotoxicityofhumanwildtypeandmutanttauintheearly
stages of embryonic development [26]. These experiments
revealed that in spite of the pan-neuronal expression of
tau in these transgenic lines, diﬀerent anatomical patterns
of toxicity in the CNS of these ﬂies could be observed
depending on whether the expressed isoform was wild
type or mutant. While human WT tau was observed to
be hyperphosphorylated at speciﬁc sites and caused severe
abnormalities in the development of the mushroom body
(MB) of the animals, the FTDP17 mutant isoform led to
signiﬁcantly less severe aberrations in MB development. The
data from these experiments in D. melanogaster suggest
that not only high levels of phosphorylation are required
to mediate tau toxicity but also that modiﬁcation has to
take place at speciﬁc phosphorylation sites, and that tau
toxicity is cell type-dependent. Another study points in
the same direction, coming to the conclusion that speciﬁc
phosphorylations at various sites modulate tau toxicity in a
synergistic manner [27].
Modeling of Aβ plaque formation in D. melanogaster
has been another objective of animal studies. The transgenic
expression of human WT or mutant APP led to neuronal
death in the brain already at the larval stage of development
[28]. The severity of the symptoms was proportional to
the concentration of Aβ and the C-terminal fragment of
APP. Clues exist that the diﬀerent forms of Aβ as soluble,
oligomeric, and insoluble plaque deposits exhibit diﬀerent
toxicities towards cells. This ﬂy model together with the
recently generated speciﬁc antibodies against the diﬀerent
types of Aβ-aggregates [29, 30] could be used to address
this question. D. melanogaster has also been successfully
employed in the study of the inﬂuence of oxidative stress on
the pathology of Alzheimer’s disease. Lowering the antiox-
idant defenses of animals which expressed R406 mutant
human tau increased tau toxicity while the antioxidant α-
tocopherol (vitamin E) was able to alleviate the eﬀects of tau
toxicity [31].4 International Journal of Alzheimer’s Disease
Table 1: Overview of the most widely used models for studying Alzheimer’s disease.
Model Advantages Drawbacks
Mus musculus
(mouse)
(i) Highly evolved organism, brain anatomy, and
metabolism close to humans, results often
extrapolatable to humans
(ii) Cognitive symptoms of neurodegeneration
can be assessed
(iii) Generation of conditional transgenic models
possible
(i) Relatively long breeding/development time
(ii) Ethical concerns
(iii) Not suitable for drug screening
(iv) Expensive
Danio rerio
(zebraﬁsh)
(i) Ex-utero development in transparent capsule
allows for live imaging of neurodegenerative
processes
(ii) Short life cycle
(iii) Genetic manipulation tools available
(i) Brain anatomy and genetic setup distinct from
humans
(ii) Behavior not suﬃciently studied, diﬃcult to
evaluate cognitive deﬁcits
Caenorhabditis
elegans (nematode)
(i) Simple anatomy,
(ii) Easy laboratory culture, short life cycle
(iii) Genetic manipulation tools highly advanced
(i) Brain anatomy and genetics distinct from
humans
(ii) Cognitive/behavioral deﬁcits diﬃcult to assess
Drosophila
melanogaster
(fruit ﬂy)
(i) Reference model for genetic studies
(ii) Suitable for drug screening
(iii) Short generation times, low maintenance
costs
(iv) genetic manipulation tools highly advanced
(i) Brain anatomy and genetics distinct from
humans
(ii) Cognitive/behavioral deﬁcits diﬃcult to assess
In vitro cell culture
models
(i) Direct monitoring of parameters over time
possible
(ii) Extremely valuable for high-throughput
screening for therapeutic drugs
(iii) Easy handling, economic
(i) Organ structure not conserved, environmental
cues/interaction with other organs are not taken
into account
(ii) Ethical considerations in the case of human
embryonic/fetal tissue as source material
Another application of the fruit ﬂy with direct clinical
relevance is that of a model organism for ﬁrst round drug
screening in AD. Given its extremely short development
period,beinganorganismwhichischeapandeasytomanip-
ulate even in large numbers and the low ethical restrictions
when working with ﬂies, D. melanogaster presents an overall
advantageous choice. In a very recent study, a Drosophila
model was described using the ﬂy’s notal bristles as a tool
for assessing tau-induced toxicity [32]. The authors propose
the use of this model for the screening of possible drugs for
use in AD therapy. While the fruit ﬂy presents a number
of advantages as a suitable animal model for AD, there are
also certain pitfalls. One major restriction when trying to
extrapolate experimental data gained with D. melanogaster
is its signiﬁcantly diﬀerent brain structure from humans, as
it does not possess a hippocampus for example. Due to its
small size the Drosophila brain is also diﬃcult to analyse
using stains for identiﬁcation of distinct regional expression
of histopathological markers. Last, memory impairment
and cognitive deﬁcits in such a phylogenetically distant
organism are diﬃcult to extrapolate to compare with human
conditions.
To widen the understanding of the cellular mechanisms
involved in AD and to aid in the search for pharmacological
compounds that could be in the beneﬁt of therapeutic
interventions for tauopathies, other lower organisms are
being employed as models for the disease. Two of the most
widely used animal models at the time are the roundworm
Caenorhabditis elegans and the zebraﬁsh (Danio rerio). The
advances that these models provided have been summarized
in recentliterature reviews[33,34]forC.elegansand[35,36]
for D. rerio, respectively. C. elegans is a small organism with
a short life span that allows for high throughput manipu-
lation and drug screening applications, while the zebraﬁsh,
another well-suited organism for studying neurodegenera-
tion, presents the advantage of being completely transparent
in its larval development state, allowing continuous in vivo
observation of processes taking place in its exposed nervous
system. Paquet and coworkers [37] generated a ﬂuorescently
labeled tau transgenic zebraﬁsh model. Using this animal,
the authors were able for the ﬁrst time to trace directly
neurodegenerative processes taking place in the ﬂuorescently
stained larvae and to visualize the resulting neuronal cell
death via time lapse microscopy in vivo. In addition, they
employed this novel model as a tool for drug screening
of GSK-3 inhibitors and have validated one promising
compound termed AR-534.
2.2. Mouse Models. Choosing a neuroanatomy which more
closely resembles the human brain, several mouse models
of AD and other tauopathies have been developed in the
last ﬁfteen years. Earlier models fell into two main groups,
according to the AD hallmark lesion (amyloid plaques or
neuroﬁbrillary tangles) mimicked in each model, but more
recent approaches have generated models exhibiting both
features simultaneously.
2.2.1.APP/AβModeling. Severaltransgenicmouselineshave
been generated which express one of the mutant forms ofInternational Journal of Alzheimer’s Disease 5
APP. Most of these transgenic lines exhibited senile plaques
as Aβ depositions and also the characteristic behavioral
deﬁcits reminiscent of AD in animal models. The ﬁrst of the
transgenic animals expressed the human mutant V717F APP
form driven by the platelet-derived growth factor (PDGF)
mini promoter [38]. Aβ plaque formation was observed in
the test animals as well as memory impairment, especially
related to spatial learning. When compared to wild type
mice, the transgenic animals showed a signiﬁcantly more
severe decline in memory as assessed by a modiﬁcation
of the Morris water maze experiment. Another model
expressedadiﬀerentmutantAPPform,theAPPSW (Swedish)
double mutation inserted into a hamster prion protein
(PrP) cosmid vector [39]. The animals presented memory
and spatial learning deﬁcits at 9 months of age. β-amyloid
concentrations increased ﬁvefold in Aβ40 and 14-fold in
Aβ42, and the deposits could be stained with Congo red
especially in the cortical and limbic regions of the brain.
In a third model that overexpressed APP sevenfold, amyloid
plaques appeared as soon as at six months of age in the tested
mice. In contrast to the other two cited studies, these mice
showed signiﬁcant neuronal cell death besides the plaque
deposits, speciﬁcally of pyramidal neurons in the CA1 region
of the hippocampus, with the plaques seemingly aﬀecting
cell integrity in the adjacent neurons. Several experiments
in transgenic mice have shown that amyloid plaque forma-
tion can promote tau pathology [40, 41]. When crossing
human APP transgenic mice with tau expressing strains, or
administering Aβ42 intracerebrally, tau phosphorylation was
enhanced and NFT depositions increased in concentration.
Interestingly however, when hAPP mice were crossed with
tau knockout animals, no memory or learning deﬁcits could
be detected in spite of the massive deposition of plaques in
thesemice[42].Theseﬁndingsunderscoretheimportanceof
the presence of tau protein for the induction of the disease as
inthisanimalmodelamyloid-mediated toxicity wasnulliﬁed
by the absence of tau. The level of neurotoxicity exerted by
Aβ also depends on its length as was revealed in a transgenic
mouse study carried out by McGowan and coworkers
[43], as transgenic mice which express only Aβ40 did not
develop any senile plaques while Aβ42-expressing animals
did.
Ad i ﬀerent mechanism of proteolytic modiﬁcation of
the Amyloid precursor protein is the cleavage at aspartate
residue 664 (D664) by caspases. Previous studies suggested
that this cleavage, alternative to the described catalytic
mechanisms involving secretases, could play a key role in the
pathogenesis of AD [44, 45]. To address this question, Harris
and coworkers used two transgenic mouse lines carrying the
APP gene with (B254) and without (J20) the caspase-speciﬁc
cleavage site and studied the possible implication of the
resulting products, the C31 and Jcasp fragments, in AD [46].
Although these products had been described before to cause
cell death in vitro, in these in vivo experiments, histological
and behavioral assessment of the test animals did not reveal
signiﬁcant diﬀerences between the B254 and J20 mice. The
authors came to the conclusion that caspase cleavage of APP
does not play a critical role in the generation of AD-related
abnormalitiesinthesetransgenicmice,andthatthereforethe
D664 cleavage site of APP would not be a suitable target for
the development of therapeutic interventions.
Recently, the diﬀerential toxicity of soluble Aβ oligomers
and ﬁbrillary Aβ plaques has been discussed [47]. In a
study with mice, animals which overexpressed the “Arctic”
mutation were compared to mice overexpressing wildtype
Aβ [48]. While the mutant Aβ (AβE22G) led to the marked
formation of amyloid plaques, it also lowered the con-
centration of a speciﬁc nonﬁbrillar Aβ-assembly (Aβ∗56).
Remarkably, both strains showed similar behavioral and
neuronal deterioration when normalized for Aβ∗56 levels,
while the number of plaques was very diﬀerent. The authors
ofthestudyconcludedthatAβ∗56concentrationsareamore
suitable marker for AD-related functional deﬁcits than the
amount of Aβ deposited in the form of plaques. Therapeutic
approaches that lead to the breakdown of ﬁbrillary Aβ
but possibly increase the levels of soluble oligomers could
therefore be counterproductive.
In view of these data, therapeutic interventions which
blocktheproductionofAβmonomersandsolubleoligomers
should be explored. This could be achieved by inhibiting
the secretases involved in APP processing. These enzymes
however are involved in other physiological processes as
well, and it may therefore be detrimental to indiscriminately
reduce their activity. Recent strategies avoid this problem, as
in the case of some nonsteroidal anti-inﬂammatory drugs
(NSAIDs) which do not alter secretase activity but alter its
cleavage site speciﬁcity resulting in the generation of the less
toxic 38 residue Aβ insteadofthehighlyamyloidogenicAβ42
[49]. The introduction of immunotherapeutic treatments
could also lead to the speciﬁc elimination of Aβ oligomers
and might prevent their formation. Positive eﬀects of this
approach have been described in a transgenic mouse model
[50] and were also assessed in humans in a small cohort of
AD patients [51].
2.2.2. NFT Modeling. Transgenic mice carrying cDNAs
which encode either the largest or the smallest human tau
isoform have been generated. Later, mouse models which
expressthemutantisoformoftaufoundinFTDP-17patients
werealsodeveloped,aswellasmicethatmodelthediseasevia
the overexpression of certain kinases which play a key role in
thehyperphosphorylationoftauinADandrelateddisorders.
The ﬁrst transgenic mouse which expressed the longest
tau isoform under control of the human Thy-1 promoter
showed tau phosphorylation at sites which are usually found
to be modiﬁed in PHFs and presented localization of human
tau in neuronal soma, axons, and dendrites. These mice
exhibit modest expression of human tau protein (approxi-
mately 10% of total tau in the animals) and did not exhibit
neuroﬁbrillary tangles [52]. However, the histopathology
observed in these animals reﬂects an early stage of AD prior
to the formation of neuroﬁbrillary tangles, in which hyper-
phosphorylated forms of tau are localized in the soma and
dendritesofneuronalcells.Inanothermousemodelinwhich
the shortest human tau isoform was overexpressed [53]
underthe murine HMGCoA reductasepromoter, transgenic
tau could be detected in the somatodendritic compartment,
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transgenic mouse models were designed using stronger
promoters, resulting in increased expression of human tau
in these animals until eventually brain tau aggregates could
be detected, although the formation of NFTs still remained
elusive [54, 55]. These models showed not only AD-like
symptoms in brain cells but also exhibited spheroidal tau
aggregates in the spinal cord resulting in motor symptoms in
the animals characteristic more of amyotrophy [56]. While
transgenic mice with excessive overexpression of human
tau are not viable, lines that overexpress tau less than
tenfold have been generated and tau inclusions have been
observed in cortical, brain stem, and spinal cord neurons,
accompanied by other symptoms such as axon degeneration,
decrease of microtubules, and motor deﬁcits. Staining of
the inclusions with the AD pathology-speciﬁc dyes Congo
red and Thioﬂavin S revealed increasing insolubility of
the aggregates over time and NFT-like inclusions could be
detected in old animals (18 to 20 months) [57]. Other
models with the tau gene under the control of the PrP
promoter led to the expression of high levels in certain
types of neurons and glial cells. Here, ﬁbrillary structures
c o u l db ed e t e c t e di ng l i a lc e l l s( o l i g o d e n d r o c y t e s )a sw e l la s
neurons [40]. The phenotype however was still not severe.
In a mouse model expressing three isoforms of human tau
simultaneously, structures were observed which were similar
to the astrocytic plaques that characteristically appear in the
gray matter in cases of Corticobasal Degeneration (CBD),
although neuronal cells were not equally aﬀected, as they did
not show any ﬁbrillary lesions [58].
While to this day no mutations have been found in
the tau-encoding MAPT gene in AD patients, molecular
analysisofanothertauopathy,frontotemporaldementiawith
parkinsonism linked to chromosome 17 (FTDP-17), has
revealed characteristic mutations in this gene. Some of them
like the P301L or the R406W mutations have been observed
tolowertau’spotentialtopromotemicrotubulestability[59].
Inmousemodelsexpressingahumantauisoformcontaining
the P301L mutation [60], reviewed in [61], it was found that
this mutation reduces the aﬃnity of tau for microtubules.
In one study, the mice showed NFTs in the brain as well
as in the spinal cord alongside with a substantial reduction
in the number of motor neurons [60]. Furthermore, the
animals developed severe behavioral deﬁcits which emulate
neurological symptoms of the disease in humans. In another
study also employing mice overexpressing human tau with
the P301L mutation [40], short tau ﬁlaments were isolated
from the brains of the test animals. Interestingly, one study
revealed that when the expression of mutant P301L tau was
suppressed after a period of overexpression, the behavioral
symptoms in these mice could be reversed, while the insol-
uble NFTs were not removed but continued to accumulate.
This result hints at the possibility that soluble tau rather than
its ﬁbrillary deposits is the cause of neuronal cell death in
Alzheimer’s disease [62]. A triple transgenic mouse model
expressing the mutant transgenes PS1 (M146V), APPSW,
and P301L tau was generated by the group of LaFerla to
examine the interactions between beta-amyloid, neuronal
dysfunctionandneuroﬁbrillarytangles[63].These3xTg-AD
micedevelopedbothoftheclassicalhallmarksofAlzheimer’s
inhumanpatients,senileplaquesandneuroﬁbrillarytangles,
and furthermore, synaptic plasticity and neuronal long-term
potentiation were impaired in these animals in a manner
which could be related to Aβ formation.
In 2002, a transgenic mouse was created that expressed
taubearingtheP301Smutation.Thismutationisresponsible
in humans for an early onset of the pathological signs of
FTDP-17 [64]. In this model, numerous PHFs consisting
of tau ﬁlaments could be detected in the brains and spinal
cords of the animals. Another observation was that motor
neurons were the cell type where the highest concentrations
of tau could be detected. Consistent with the ﬁndings in
human patients where the P301S mutation is related with
an earlier onset of FTDP-17 as compared to the P301L
mutation, neuronal cell death was highly elevated (49%) in
mice which overexpressed human P301S tau. Colocalization
of hyperphosphorylated tau deposits and MAP kinases
hinted at the possible implication of these enzymes in
tau modiﬁcation. In another study which compared the
development of neurodegenerative signs in P301S mutant
transgenic and wild type mice, neuroﬁbrillary lesions could
be detected in the transgenic animals at the age of 9 to 12
months, accompanied by the massive loss of hippocampal
and cortical neurons [65]. Interestingly, synapse loss in the
hippocampus and deﬁcits in synaptic function could be
observed long before the formation of NFTs, at about three
monthsofage.Giventhatearlymicroglialactivationwasalso
observed and that tau pathology could to some extent be
reverted by administration of the immunosuppressive drug
FK506, the authors of the study established a link between
neuroinﬂammation and the early stages in the development
of tauopathies.
The implication of an improperly controlled cell cycle
in neurodegenerative diseases has also been described in
the literature [66]. In degenerating neurons elevated con-
centrations of proteins associated with the cell cycle such
as cyclins, cyclin-dependent kinases, and the products of
proto-oncogenes such as c-myc, can often be detected. Two
studies investigate the eﬀects of cell cycle reentry mediated
by transduction with c-myc, using an in vitro cell culture
model [67]a sw e l la sat r a n s g e n i cm o u s em o d e l[ 68].
Induced cell cycle reentry led to the death of neurons,
gliosis, and cognitive impairment in the mouse model, thus
indicating that this loss of control in mature, postmitotic
neurons may contribute to the pathogenesis of diseases like
Alzheimer’s. Interestingly, forced cell cycle re-entry led to the
phosphorylation of tau and to the formation of tangle-like
structures in the in vitro model, providing further evidence
for a possible causal connection between the cell cycle and
AD.
Another interesting study addresses the possible contri-
bution of insulin to the pathogenesis of AD [69]. As insulin
has been described to be involved in the metabolism of
both Aβ and tau, the researcher studied the possible eﬀect
of artiﬁcially induced Diabetes mellitus (DM) on the brain
cells of pR5 transgenic mice which expressed the P301L
human mutant tau and produced neuroﬁbrillary tangles.
After drug induced-insulin depletion, tau phosphorylation
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though remarkably only the transgenic animals produced
massive deposits of nonsoluble hyperphosphorylated tau
protein. The authors came to the conclusion that DM is
capable of triggering an earlier onset of a preexisting tau
pathology in susceptible animals and that diabetes might
cause an abnormal phosphorylation of tau via the elevation
of glucose levels. Given the high rates of comorbidity of
AD and DM in the human population, this line of research
deserves further investigation as it might unveil new insights
on the pathogenesis of AD.
In a complex yet very elegant survey, a genome wide
search strategy employing lentivectors led to the identiﬁ-
cation of a retroposed gene in mouse [70]. This Rps23r1
gene normally encodes for the ribosomal protein S23 but
in the retroposed form is transcribed in the reversed sense,
expressing a functional protein which is localized integrated
in cell membranes of the cerebral cortex and hippocampus.
Intriguingly, overexpression of Rps23r1 reduced levels of
Aβ, GSK-3 activity, and tau phosphorylation. The proposed
mechanismofthiseﬀectconsistsofaninitialinteractionwith
adenylate cyclases upregulating cellular cAMP levels, which
in turn activates protein kinase A (PKA). This activation
results in the inhibition of GSK-3, a kinase that is involved
in tau phosphorylation and Aβ generation.
Given that these aberrant phosphorylations of tau play
a key role in the development of Alzheimer’s disease,
another important strategic approach is to identify the
phosphorylation sites that are connected to the formation
of aggregates and to identify the responsible enzymes and
pathways for these tau modifying reactions, namely, the
kinases and phosphatases.
The ﬁrst generation of transgenic mice expressing GSK-
3β, a kinase involved in many physiological pathways, was
generated using both ubiquitous or CNS-speciﬁc promoters
[71]. In all cases however, though slight increases in the
phosphorylation levels of tau could be observed, no overex-
pression of the enzyme took place. This is probably due to
thenarrowwindowofconcentrationsinwhichGSK-3canbe
expressed in cells, below and above which the lack or excess
of GSK-3 activity proves lethal.
Considering the narrow concentration range of GSK-3
that permits cell viability, a model was created with GSK-
3 gene expression adjustable by means of a conditional
tetracycline regulated system under the control of the CaM
kinase II α-promoter [72]. The advantage of animal models
employing the tetracycline regulation system lies in the
possibility to carry out reversible studies [73]. In this
mouse model, GSK-3β overexpression was conﬁned to a
particular set of cortical and hippocampal neurons. The
overexpression of the kinase led to hyperphosphorylation of
tau as detected by speciﬁc antibodies and showed how tau
phosphorylation lowers its aﬃnity for microtubule binding.
Behavioral deﬁcits related to Alzheimer’s disease however,
could be observed in this animal model by applying the
Morris water maze test [74]. In spite of these ﬁndings,
the correlated deposition of insoluble tau neuroﬁbrillary
tangles could not be observed. The shutdown of GSK-
3 overexpression in turn leads to normal GSK-3 activity,
normal phospho-tau levels, diminished neuronal death, and
the suppression of the cognitive deﬁcits. These ﬁndings
further support the potential of GSK-3 inhibitors in the
treatment of AD [75].
To further study the involvement of GSK-3, transgenic
mice that overexpress GSK-3β were crossed with FTDP-
17 mutant tau mice [75]. This AD animal model, termed
GSK-3/VLW, shows tau hyperphosphorylation in CA1 hip-
pocampal neurons, the region where the expression patterns
of both transgenes overlap. Tau ﬁlaments with a PHF-like
structure were found in GSK-3/VLW mice but not in single
transgenic mice expressing either GSK-3β or FTDP-17 tau
alone. PHF-like ﬁlament formation in GSK-3/VLW mice
was accompanied by thioﬂavin-S staining, indicating the
presence of senile plaques. All these data suggest that there is
a synergistic contribution of both types of tau modiﬁcation,
hyperphosphorylation and missense mutations, to induce
aberrant tau aggregation.
The same animal model has been utilized to study
the possible eﬀects of lithium, a GSK-3 inhibitor used for
treating aﬀective disorders with well-documented eﬀects in
humans [76]. Two questions were addressed: ﬁrst, whether
chronic lithium treatment is able to prevent the formation
of aberrant tau aggregates (formed by overexpression of
FTDP-17 tau and GSK-3β); and second, whether lithium can
revert already formed tau aggregates and NFTs to achieve
their clearance in aged animals. The results indicated that
lithium is capable of preventing the development of tau
pathology when administered early in disease progression.
On the other hand, if lithium administration is initiated
at late stages, tau hyperphosphorylation is reduced but tau
aggregation cannot be reversed. The data supports studies
describing novel GSK-3 inhibitors as new pharmacological
treatments of this kind of neurodegenerative disorders, as
reviewed byAvila and Hern´ andez [77].
A second transgenic animal expressing a constitutively
active form of the kinase, GSK-3β(S9A), has been cross-bred
with transgenic mice that overexpress the longest human tau
isoform [55]. The number of axonal enlargements present
and the motor impairment typical for these tau transgenic
animals were reduced in the double transgenic mice [78].
Thus, taking into account all these data it seems that GSK-
3 could have diﬀerent functions in diﬀerent neurons and
in diﬀerent regions of the brain, while the hippocampal
d e n t a t eg y r u ss e e m st ob em o r es u s c e p t i b l et od e g e n e r -
ation in transgenic mice overexpressing GSK-3β [75]. A
recent publication examines the possible role of GSK-3 in
tau phosphorylation in the dentate gyrus [79]. Previously
generated transgenic mice which overexpress GSK-3 in the
dentate gyrus were crossed with a tau knockout strain in
order to verify if GSK-3 mediated phosphorylation of tau is
the cause of neurodegeneration in the dentate gyrus. When
compared to tau-expressing control animals, the authors
observed that the signs of neurodegenerative damage were
signiﬁcantly attenuated in the absence of tau. Therefore,
hyperphosphorylationoftauisproposedtobeacausalfactor
of the histopathological lesions found in the animals.
Very recently, the role of caspases in AD was reevaluated
in a study by Calignon and coworkers [80]. Using the
transgenic Tg4510 mouse strain, the researchers observed8 International Journal of Alzheimer’s Disease
that tangle free cells which showed caspase activation formed
NFTs within 24 hours. Furthermore, administration of wild
type tau into wild type animals led to caspase activation
and eventually to tangle formation. The data from this study
suggest that caspase activation of tau could be a direct cause
of tangle formation, and as has been pointed out in various
recent articles, that the AD typical neuroﬁbrillary deposits
are the ﬁnal histological outcome of a neurodegenerative
process, rather than the cause of it.
3.CellCultureModels
While research models in animals allow studies in the whole
organism within a reasonable time, there also exists a need
for the possibility to investigate disease-related processes in
human cells. Live human neuronal cells however are diﬃcult
to access for study. Therefore, recently cell culture-based
approaches are being developed, relying on the derivation
and propagation of neuronal cells from diﬀerent types of
human tissue.
One widely employed model for neuronal cells in culture
is the human neuroblastoma line SHSY5Y, which was used
to elucidate the role of leptin in Alzheimer’s disease. Leptin
has recently been proposed as another factor related to
the susceptibility of contracting AD. It is an endocrine
hormone with implications in food intake regulation as
well as processes of learning and memory, for example,
in long-term potentiation (LTP) [81]. Epidemiological data
from human populations suggest a signiﬁcantly lower risk
of developing AD for people with higher leptin blood
levels [82]. The mechanism of action is probably the same
as one described for the physiologically closely related
peptide insulin. Experiments with diﬀerentiated SHSY5Y
human neuroblastoma cells indicate that both compounds
are capable of reducing the level of tau phosphorylation
via inactivation of GSK3-β [83]. Another study revealed a
possibleprotectiveeﬀectofleptinonneuronalcellsagainstβ-
amyloidtoxicity[84].InasSHSY5Ycellculturemodelaswell
as in a transgenic mouse model, leptin was found to reduce
toxic Aβ levels. Leptin reduces the activity of β-secretase, one
of the enzymes that cleaves APP, which could probably be the
underlying mechanism of the Aβ reducing eﬀect of leptin.
Recently, the applicability of cell culture models has
been vastly improved by the possibility of deriving patient-
speciﬁc cell lines that can be propagated in vitro. Patient-
speciﬁc ﬁbroblasts for example, can be reprogrammed to
induced pluripotent stem (iPS) cells and then diﬀerentiated
into neuronal cell types similar to those found in the
hippocampus or cerebral cortex. This allows the generation
of cell models that reproduce certain disease-speciﬁc features
in vitro, without ethical concerns and which are easily
accessible for analysis and manipulation [85].
The groundbreaking work in iPS generation was con-
ducted by the group of Yamanaka, who succeeded in creating
pluripotent stem cells ﬁrst by transducing mouse embryonic
ﬁbroblasts with a set of four genes encoding the factors
Oct3/4, Sox2, c-Myc, and Klf4. When grown under culture
conditions for embryonic stem (ES) cells, these iPS cells
showed the morphological traits, growth potential, and
immunomarkers of ES cells [86]. Later, the authors were able
to generate iPS cells from adult human dermal ﬁbroblasts
using the same four factors [87]. Today, several cell lines
speciﬁc for various neurodegenerative diseases have been
generated with the objective of creating human in vitro
models. Examples are Amyotrophic lateral sclerosis (ALS)
[88], Parkinson disease (PD), and Huntington disease (HD),
reviewed in [89]. In the case of ALS, Dimos and coworkers
[88] were able to derive iPS cells from ﬁbroblasts of an 82-
year-old patient suﬀering from the disease and subsequently
diﬀerentiate these iPS cells into motor neurons, the cell
type aﬀected by ALS. To date, the generation of Alzheimer’s
speciﬁc iPS cells has not been published, but their generation
and diﬀerentiation to neuronal types involved in disease
progression hopefully will be accomplished soon, oﬀering a
novel tool to study the pathological processes, such as tau
phosphorylation and tangle formation, whichsofarhave not
been completely recapitulated in animal models.
Another strategy is the use of fetal human neural stem
c e l l s( h N S C )t oc r e a t ec e l lm o d e l sb yd i ﬀerentiation of
these cells to neuronal types of interest. We have established
a method for the diﬀerentiation of hNSC to postmitotic
neurons which express the neuronal markers tau and βIII-
tubulin. These neurons were derived from human fetal
forebrain tissue [90] and are viable in cell culture for
weeks. This model permits the study of eﬀects of candidate
therapeutic drugs on tau expression or phosphorylation
state. Furthermore, these cells can be transduced with viral
vectors to overexpress AD-related genes, such as those
encoding tau or GSK-3 allowing the study of the consequent
alterations, including the formation of tangles and plaques.
Additionally, the eﬀect of tau-overexpression on neural
stem cells (in their undiﬀerentiated state) is an interesting
topic, as brains aﬀected by AD show high levels of tau
phosphorylation in regions, such as the hippocampus, where
neural stem cells reside and are involved in adult neurogene-
sis. As research in neural stem cells and neurodiﬀerentiation
continues to make technological leaps, further contributions
to Alzheimer research can be expected soon by means of
creation of human cell models that imitate speciﬁc aspects
of the disease.
4. Conclusion
In summary, a variety of animal models have been generated
which reproduce either the Aβ or tau histopathological
hallmark lesions of AD as well as transgenic animals which
exhibit both features simultaneously. Some of these models
reproducethelesionsaswellastherelatedbehavioralimpair-
ments, while suggesting that both plaques and tangles may
have synergistic eﬀects in driving the disorder rather than
developing independently from each other. This observation
is strengthened by the notion that the transgenic mouse
models most successfully reproducing AD-like pathology are
the ones which combine overexpression of tau and APP,
like the 3xTg-AD mice [63]. The animal models shed light
on mechanisms of progression of tauopathies and their
application as drug screening systems pave the way for
the development of future treatments of dementia. Due toInternational Journal of Alzheimer’s Disease 9
the additional need for human models combined with the
impossibilityofconductingbasicresearchinhumansinvivo,
the use of iPS cells and neural stem cell cultures derived
from human fetal and adult tissue is being established as an
alternative and complementary route. While this approach
does not hold the advantages of conserving the integrity of
the biological system under study, they do allow the study
of molecular interaction and biochemical pathways in an all-
human system, a point of high relevance due to the human
speciﬁcity of many aspects of AD.
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